The role of another PPARγ agonist—pioglitazone, used as an antidiabetic drug in type 2 diabetes—in the risk of IBD was investigated in n = 12,763 ever users and n = 12,763 never users in Taiwan. Here, PPARG is linked to irritable bowel syndrome.